1,1-Dimethylethyl 4,7,10,13-tetraoxa-16,17-dithiaoctadecanoate | 564476-34-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,1-Dimethylethyl 4,7,10,13-tetraoxa-16,17-dithiaoctadecanoate
• 英文别名: tert-butyl 3-[2-[2-[2-[2-(methyldisulfanyl)ethoxy]ethoxy]ethoxy]ethoxy]propanoate
• CAS: 564476-34-2
• 化学式: C₁₆H₃₂O₆S₂
• 分子量: 384.558
• InChiKey: RDKLGUSHGUJDRL-UHFFFAOYSA-N

物化性质

• 沸点：
  454.5±40.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  24
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  114
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,1-Dimethylethyl 4,7,10,13-tetraoxa-16,17-dithiaoctadecanoate 在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以67%的产率得到3-[2-[2-[2-[2-(甲基二硫烷基)乙氧基]乙氧基]乙氧基]乙氧基]丙酸
  参考文献：
  名称：

  Synthesis of Taxoids with Improved Cytotoxicity and Solubility for Use in Tumor-Specific Delivery

  摘要：

  To develop effective taxane-antibody immunoconjugates, we have prepared a series of modified taxanes that have both improved toxicity and solubility in aqueous systems as compared to paclitaxel (1a). These taxanes have been modified at either the C-10 or C-7 position and were found to be very cytotoxic against both normal and multi-drug-resistant (MDR) cells, as well as up to 30 times more soluble than paclitaxel in various buffer systems.

  DOI：

  10.1021/jm049705s
• 作为产物：
  描述：

  15-(2-ethoxythiocarbonylthio)-4,7,10,13,16-pentaoxahexadecanoic acid tert-butyl ester 在 sodium phosphate buffer 、 hydroxylamine buffer 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 1.5h， 生成 1,1-Dimethylethyl 4,7,10,13-tetraoxa-16,17-dithiaoctadecanoate
  参考文献：
  名称：

  Synthesis of Taxoids with Improved Cytotoxicity and Solubility for Use in Tumor-Specific Delivery

  摘要：

  To develop effective taxane-antibody immunoconjugates, we have prepared a series of modified taxanes that have both improved toxicity and solubility in aqueous systems as compared to paclitaxel (1a). These taxanes have been modified at either the C-10 or C-7 position and were found to be very cytotoxic against both normal and multi-drug-resistant (MDR) cells, as well as up to 30 times more soluble than paclitaxel in various buffer systems.

  DOI：

  10.1021/jm049705s